WallStreetZenWallStreetZen

NASDAQ: EXEL
Exelixis Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for EXEL

Based on 16 analysts offering 12 month price targets for Exelixis Inc

Min Forecast
$38.00-3.82%
Avg Forecast
$46.31+17.22%
Max Forecast
$60.00+51.86%

Should I buy or sell EXEL stock?

Based on 16 analysts offering ratings for Exelixis Inc.

Buy
Strong Buy
7 analysts 43.75%
Buy
3 analysts 18.75%
Hold
6 analysts 37.5%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their EXEL stock forecasts and price targets.

EXEL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-17
lockedlocked$00.00+00.00%2025-09-17
lockedlocked$00.00+00.00%2025-09-17
lockedlocked$00.00+00.00%2025-08-12
lockedlocked$00.00+00.00%2025-07-30
Truist Securities
Bottom 3%
3
Strong BuyMaintains$49.00+24.02%2025-07-29
RBC Capital
Top 14%
87
HoldMaintains$45.00+13.90%2025-07-29
JMP Securities
Top 16%
85
BuyReiterates$50.00+26.55%2025-07-29
Guggenheim
Top 27%
74
Strong BuyReiterates$45.00+13.90%2025-07-29
Stifel Nicolaus
Top 36%
65
HoldMaintains$41.00+3.77%2025-07-29

1 of 2

Forecast return on equity

Is EXEL forecast to generate an efficient return?

Company
69.43%
Industry
94.29%
Market
-65.75%
EXEL's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EXEL forecast to generate an efficient return on assets?

Company
52.72%
Industry
36.43%
EXEL is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EXEL earnings per share forecast

What is EXEL's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$2.34+8.84%
Avg 2 year Forecast
$2.73+26.98%
Avg 3 year Forecast
$3.70+71.98%
EXEL's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

EXEL revenue forecast

What is EXEL's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$2.3B+4.24%
Avg 2 year Forecast
$2.6B+17.31%
Avg 3 year Forecast
$3.1B+37.43%
EXEL's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EXEL earnings growth forecast

How is EXEL forecast to perform vs Biotechnology companies and vs the US market?

Company
18.14%
Industry
4.79%
Market
15.38%
EXEL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
EXEL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
EXEL's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

EXEL revenue growth forecast

How is EXEL forecast to perform vs Biotechnology companies and vs the US market?

Company
10.83%
Industry
88.41%
Market
11.64%
EXEL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EXEL's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EXEL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EXEL$39.51$46.31+17.22%Buy
BBIO$56.50$68.08+20.49%Strong Buy
MRNA$26.25$32.38+23.33%Hold
BMRN$52.47$96.71+84.32%Strong Buy
ROIV$16.40$19.94+21.57%Strong Buy
View Top Biotech Stocks

Exelixis Stock Forecast FAQ

Is Exelixis Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 16 Wall Street analysts covering (NASDAQ: EXEL) stock is to Buy EXEL stock.

Out of 16 analysts, 7 (43.75%) are recommending EXEL as a Strong Buy, 3 (18.75%) are recommending EXEL as a Buy, 6 (37.5%) are recommending EXEL as a Hold, 0 (0%) are recommending EXEL as a Sell, and 0 (0%) are recommending EXEL as a Strong Sell.

If you're new to stock investing, here's how to buy Exelixis stock.

What is EXEL's earnings growth forecast for 2025-2027?

(NASDAQ: EXEL) Exelixis's forecast annual earnings growth rate of 18.14% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.79%, and it is also forecast to beat the US market's average forecast earnings growth rate of 15.38%.

Exelixis's earnings in 2025 is $602,298,000.On average, 8 Wall Street analysts forecast EXEL's earnings for 2025 to be $629,933,899, with the lowest EXEL earnings forecast at $613,781,748, and the highest EXEL earnings forecast at $648,778,076. On average, 7 Wall Street analysts forecast EXEL's earnings for 2026 to be $734,922,882, with the lowest EXEL earnings forecast at $613,781,748, and the highest EXEL earnings forecast at $901,828,445.

In 2027, EXEL is forecast to generate $995,376,321 in earnings, with the lowest earnings forecast at $734,922,882 and the highest earnings forecast at $1,265,251,849.

What is EXEL's revenue growth forecast for 2025-2027?

(NASDAQ: EXEL) Exelixis's forecast annual revenue growth rate of 10.83% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 88.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.64%.

Exelixis's revenue in 2025 is $2,230,005,000.On average, 9 Wall Street analysts forecast EXEL's revenue for 2025 to be $625,801,640,443, with the lowest EXEL revenue forecast at $611,854,257,830, and the highest EXEL revenue forecast at $642,048,012,585. On average, 9 Wall Street analysts forecast EXEL's revenue for 2026 to be $704,221,411,620, with the lowest EXEL revenue forecast at $673,439,718,559, and the highest EXEL revenue forecast at $761,495,863,178.

In 2027, EXEL is forecast to generate $825,039,233,842 in revenue, with the lowest revenue forecast at $756,862,887,792 and the highest revenue forecast at $924,729,503,811.

What is EXEL's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: EXEL) forecast ROA is 52.72%, which is higher than the forecast US Biotechnology industry average of 36.43%.

What is EXEL's Price Target?

According to 16 Wall Street analysts that have issued a 1 year EXEL price target, the average EXEL price target is $46.31, with the highest EXEL stock price forecast at $60.00 and the lowest EXEL stock price forecast at $38.00.

On average, Wall Street analysts predict that Exelixis's share price could reach $46.31 by Sep 17, 2026. The average Exelixis stock price prediction forecasts a potential upside of 17.22% from the current EXEL share price of $39.51.

What is EXEL's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: EXEL) Exelixis's current Earnings Per Share (EPS) is $2.15. On average, analysts forecast that EXEL's EPS will be $2.34 for 2025, with the lowest EPS forecast at $2.28, and the highest EPS forecast at $2.41. On average, analysts forecast that EXEL's EPS will be $2.73 for 2026, with the lowest EPS forecast at $2.28, and the highest EPS forecast at $3.35. In 2027, EXEL's EPS is forecast to hit $3.70 (min: $2.73, max: $4.70).

What is EXEL's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: EXEL) forecast ROE is 69.43%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.